Partner, Frazier Healthcare
Daniel Estes joined Frazier Healthcare in 2011 and is a Principal on the Frazier Life Sciences team, focusing on investments in biopharmaceutical and specialty pharmaceutical companies. Dan is a member of the board of directors at Semnur Pharmaceuticals, and is a board observer at Atterocor. He has also been involved in Frazier’s investments in Acerta, Cidara, ProNAi, Allena, Alcresta, and Precision Dermatology (acquired by Valeant).
Prior to joining Frazier Healthcare, Dan was a consultant with McKinsey & Company’s West Coast healthcare practice. He worked with pharmaceutical, biotechnology, and life sciences tools organizations in the US and Asia, focusing on a range of R&D and business development topics.
Dan received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on understanding the role and regulation of potassium ion channels in human T cells. He also holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.